VALN
- Valneva SE
()
Overview
Company Summary
Valneva SE, commonly known as Valneva, is a biotechnology company that specializes in the development, production, and commercialization of vaccines for infectious diseases. Founded in 2013, the company is headquartered in France and has operations in Austria, Sweden, the United Kingdom, and the United States.
Valneva focuses on creating preventative and therapeutic vaccines for various diseases, including Lyme disease, COVID-19, Japanese encephalitis, and chikungunya. The company's expertise lies in utilizing its proprietary technology platforms to develop innovative vaccine candidates.
Valneva's vaccine development process involves extensive research and clinical trials to ensure safety and efficacy. The company collaborates with government agencies, non-profit organizations, and pharmaceutical companies to conduct clinical studies and commercialize its products globally.
In addition to vaccine development, Valneva also operates a commercially successful business segment known as Valneva Sweden AB. This segment focuses on manufacturing and selling injectable polio vaccines, which are used for routine immunization purposes.
Overall, Valneva plays a crucial role in addressing public health challenges by developing and manufacturing vaccines to prevent the spread of infectious diseases and improve global health outcomes.